STAT+: Pharmalittle: White House announces Covid-pill push; ‘right-to-try’ think tank is back with a new law

The Biden administration announced a series of initiatives aimed at increasing the use of antiviral pills to treat Covid-19, with a focus on Pfizer's Paxlovid.

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Our choice today is golden French toast. As always, feel free to join us. Meanwhile, here are a few items of interest. Hope you have a smashing day, and, of course, do stay in touch. …

The Biden administration announced a series of initiatives aimed at increasing the use of antiviral pills to treat Covid-19, with a particular focus on Pfizer’s Paxlovid, STAT reports. The first step will be simply to make Paxlovid and Merck’s molnupiravir, another oral antiviral treatment, available at more places. Administration officials said they plan to nearly double the number of locations where the drugs are available, including pharmacies, community health centers, urgent care centers, and Veterans Affairs clinics. Currently, the drugs are available at 20,000 locations, but the number is expected to jump to more than 30,000.

Continue to STAT+ to read the full story…